An officer plans a $159K share sale at Xeris Biopharma (XERS).
Xeris Biopharma officer Beth Hecht plans to sell 16,666 common shares, valued at approximately $159,326.96, with an approximate sale date of October 1, 2026. This intended sale follows two previous 10b5-1 sales of 16,666 shares each in August and September 2026. The transaction is being handled through Morgan Stanley Smith Barney LLC.
XERS5927663 Bond Profile: Coupon and Redemption
This article provides a detailed profile of the XERS5927663 bond issued by Xeris Biopharma Holdings, Inc. It outlines key facts such as the issuer type, issue and maturity dates, face value, and minimum denomination. The profile also includes information on the bond's 8.0% semi-annual fixed-rate coupon payments and redemption details.
Lundbeck is weighing a bid for Xeris Biopharma, per people familiar
Danish drugmaker H Lundbeck A/S is reportedly considering an acquisition of Chicago-based Xeris Biopharma, known for its injectable treatments for endocrine and rare conditions. Lundbeck has engaged advisers to assess a potential deal, though Xeris has stated it is not for sale. The news sent Xeris shares to a 2019 high, while Lundbeck's stock dipped slightly.
Xeris Biopharma Holdings, Inc. (XERS) Stock Price, News, Quote & History - Yahoo Finance
This article provides a detailed financial overview of Xeris Biopharma Holdings, Inc. (XERS), including its stock price, historical data, key financial metrics, and analyst insights. It covers the company's product offerings, pipeline, and recent performance compared to the S&P 500. The report also includes valuation measures, profitability data, and balance sheet highlights for investors.
Xeris Biopharma stock hits 52-week high at 10.08 USD By Investing.com
Xeris Biopharma's stock reached a new 52-week high of $10.08 USD, reflecting an 82% surge over six months and a 25% year-to-date gain, driven by strong gross profit margins and revenue growth. Despite this, InvestingPro analysis suggests the stock may be overvalued, with RSI indicating overbought conditions. The company recently reported strong Q2 2026 revenue of $92.1 million, exceeding estimates, and Oppenheimer reiterated an Outperform rating due to the potential of its XP-8121 drug candidate.
Xeris Biopharma Acquisition Rumors Spark Interest
Danish drugmaker Lundbeck has reportedly shown interest in acquiring Xeris Biopharma, causing a 15% surge in XERS shares, despite Xeris stating it is "not for sale." Xeris boasts a promising pipeline, including XP-8121 with projected peak annual revenues between $1 billion and $3 billion, and reported a 29% year-over-year increase in Q2 revenue, driven by strong Recorlev sales. The company maintains a solid financial foundation with $121.7 million in cash, supporting future R&D and market expansion.
Danish drugmaker eyes takeover of Chicago’s Xeris Biopharma
Danish pharmaceutical company H. Lundbeck A/S is reportedly interested in acquiring Chicago-based Xeris Biopharma. This potential takeover was reported by Bloomberg and published in Crain's Chicago Business. The article was written by Michelle F. Davis, Vinicy Chan, and Crystal Tse.
Xeris Biopharma Holdings Insider Sold Shares Worth $250,000, According to a Recent SEC Filing
Kevin McCulloch, President and Chief Operating Officer of Xeris Biopharma Holdings, sold 25,000 shares on September 28, 2026. This transaction is valued at $250,000. Further details are available to premium subscribers.
Market Chatter: Lundbeck Said to Explore Potential Xeris Biopharma Acquisition
H Lundbeck is reportedly working with advisors to explore a potential acquisition of Xeris Biopharma Holdings (XERS). This news was reported by MT Newswires. Access to the full details requires a premium subscription.
Xeris Biopharma stock hits 52-week high at 10.08 USD
Xeris Biopharma (XERS) stock recently reached a new 52-week high of $10.08, reflecting an 82% surge over six months and a 25% year-to-date gain, driven by strong gross profit margins and revenue growth. Despite this, InvestingPro analysis suggests the stock might be overvalued, with its RSI indicating overbought conditions. The company also reported Q2 2026 revenue of $92.1 million, surpassing estimates, and received an Outperform rating from Oppenheimer with an $18.00 price target, largely due to its XP-8121 candidate for hypothyroidism.
Xeris Biopharma stock rises 1.62 percent on September 24
Xeris Biopharma's stock rose 1.62% on September 24, 2026, trading at USD 8.80 on Nasdaq. The company reported Q2 2026 revenue of USD 92.1 million, a 29% increase year-over-year, with a gross margin of 86%. Xeris also provided full-year revenue guidance of USD 385 million to USD 390 million and plans to start the Phase 3 Cornerstone study for its investigational treatment XP-8121 by year-end 2026.
Xeris Biopharma Holdings, Inc. (XERS) Stock Analysis: A 50% Upside Potential Amidst Robust Revenue Growth
Xeris Biopharma Holdings, Inc. (XERS) is a healthcare company focusing on therapies for chronic endocrine and neurological diseases, with a market cap of $1.49 billion. Analysts project a 50.56% upside potential, with an average target price of $12.29, driven by robust revenue growth of 28.70%. The company is reinvesting earnings into growth initiatives, focusing on its commercialized treatments and pipeline development, despite currently having negative EPS.
Xeris Biopharma Holdings, Inc. at XP-8121 Program Overview Transcript
Xeris Biopharma Holdings, Inc. hosted a program overview for its XP-8121 candidate drug, a once-weekly subcutaneous injection of levothyroxine for hypothyroidism. The company believes XP-8121 has blockbuster potential. The presentation featured insights from Chairman and CEO John Shannon and lead endocrinologist Dr. David Robertson.
Millions of thyroid patients may get weekly shot option from Xeris (NASDAQ: XERS)
Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) has outlined a comprehensive clinical and commercial plan for XP-8121, its investigational once-weekly subcutaneous levothyroxine for hypothyroidism. The company projects potential peak net revenue of $1–3 billion for XP-8121, targeting 3–5 million inadequately controlled hypothyroid patients in the U.S. The Phase 3 registrational study, Cornerstone, is expected to begin by year-end 2026, with potential FDA approval and U.S. launch anticipated in 2030.
Xeris Biopharma COO Kevin McCulloch sells $127,308 in stock By Investing.com
Kevin McCulloch, COO of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), sold 15,000 shares of company stock for a total of $127,308, as part of a pre-established trading plan. Following the sale, McCulloch directly holds over 1.6 million shares. InvestingPro analysis indicates the stock is currently overvalued, despite the company reporting strong Q2 2026 revenues that surpassed analyst estimates.
Xeris Biopharma COO Kevin McCulloch sells $127,308 in stock
Kevin McCulloch, COO of Xeris Biopharma Holdings, sold 15,000 shares of company stock for $127,308 on September 1, 2026, pursuant to a pre-arranged trading plan. Following the sale, McCulloch directly holds over 1.6 million shares. InvestingPro analysis indicates the stock is currently overvalued, despite the company recently reporting strong Q2 2026 revenue that beat estimates, though it posted a loss per share.
Xeris Biopharma’s Beth Hecht sells $141,434 in company stock
Beth Hecht, Chief Legal Officer of Xeris Biopharma Holdings, sold 16,666 shares of company stock for a total of $141,434 on September 1, 2026. This sale follows a 37.75% return for Xeris shares over the past six months and comes after the company reported increased revenue but missed earnings expectations in its Q2 2026 financial results. The earnings miss was partially attributed to a one-time non-cash GAAP charge.
Xeris Biopharma CFO Steven Pieper sells $42,500 in shares
Xeris Biopharma's CFO, Steven Pieper, sold 5,000 shares of the company's common stock for $42,500 on September 1, 2026, as part of a Rule 10b5-1 trading plan. This transaction follows a strong 38% return for Xeris shares over the past six months and comes after the company reported better-than-expected Q2 2026 revenue but missed earnings estimates due to a non-cash GAAP charge. Mr. Pieper still directly holds over 1.35 million shares.
Xeris Biopharma CFO Steven Pieper Executes Sale of 5,000 Shares via 10b5-1 Trading Plan
Steven Pieper, CFO of Xeris Biopharma Holdings, Inc., sold 5,000 shares of the company's common stock on September 1, 2026, at $8.5 per share. This transaction was executed under a pre-established Rule 10b5-1 trading plan adopted on August 18, 2025. Following the sale, Mr. Pieper directly owns 1,356,053 shares of Xeris Biopharma common stock.
Xeris Biopharma CFO Steven Pieper sells $42,500 in shares
Xeris Biopharma CFO Steven Pieper sold 5,000 shares of the company's common stock for $42,500 on September 1, 2026, executing a Rule 10b5-1 trading plan. Despite a 38% return over the last six months, the stock is considered overvalued according to InvestingPro. This insider sale follows mixed Q2 2026 financial results, which showed revenue beating estimates but a loss per share missing expectations due to a one-time non-cash charge.
Rice Hall James & Associates LLC Takes Position in Xeris Biopharma Holdings, Inc. $XERS
Rice Hall James & Associates LLC has acquired a new position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), purchasing 300,791 shares valued at approximately $2.38 million in the second quarter. The article details other institutional investors' activities, Xeris Biopharma's financial performance, and recent insider trading. Despite mixed analyst ratings, the stock has shown upward movement, but the company missed EPS estimates in its latest quarterly report.
Why Xeris Biopharma (XERS) Is Up 6.6% After Tighter 2026 Revenue Guidance And Wider Losses
Xeris Biopharma (XERS) shares rose 6.6% despite reporting wider net losses in Q2 2026, as the company tightened its full-year 2026 revenue guidance to US$385 million–US$390 million. The company's investment narrative highlights strong revenue growth potential driven by its endocrine and diabetes portfolio, but rising costs and widening losses remain a key risk. Analysts have varying forecasts, with some predicting a significant upside to the current stock price if cost pressures ease.
Why Xeris Biopharma (XERS) Is Up 6.6% After Tighter 2026 Revenue Guidance And Wider Losses
Xeris Biopharma Holdings (XERS) saw its stock rise 6.6% despite reporting wider net losses in Q2 2026 and for the first half of 2026. The company tightened its full-year 2026 revenue guidance to US$385 million–US$390 million, offering clearer expectations. This update, alongside recent board changes, emphasizes the ongoing challenge of rising costs outpacing revenue growth for the biopharma company.
Xeris Biopharma Holdings (XERS) Could Be 23% Undervalued As Guidance Tightens And Pipeline Progress Continues
Xeris Biopharma Holdings (XERS) is gaining attention after tighter full-year revenue guidance and second-quarter results were released on August 6, 2026. The stock is considered 22.8% undervalued with a fair value of $11.14 per share, compared to its current price of $8.60. This valuation is supported by projected faster top-line growth, higher profit margins, and the anticipated launch of XP-8121 for hypothyroidism, despite widening losses being a concern for some.
Walleye Capital LLC Invests $4.84 Million in Xeris Biopharma Holdings, Inc. $XERS
Walleye Capital LLC has invested $4.84 million in Xeris Biopharma Holdings, Inc. by acquiring 611,296 shares in the second quarter, representing 0.35% of the company. Institutional investors collectively own 42.75% of Xeris. Despite reporting higher-than-expected revenue of $92.1 million, the company posted an adjusted loss of $0.18 per share, missing analyst estimates.
Mission Produce And Two Other Stocks Estimated To Be Trading Below Intrinsic Value
The article highlights three US stocks—Mission Produce (AVO), Xeris Biopharma Holdings (XERS), and Gold Royalty (GROY)—that are estimated to be trading below their intrinsic value based on future cash flow. Despite recent financial challenges for some, all three companies show strong projected earnings growth. Investors are encouraged to explore these undervalued opportunities.
XERS|Xeris Biopharma Holdings Inc|Price:8.322|Chg%:-0.168
This page provides an overview of Xeris Biopharma Holdings Inc (XERS), including its live stock price, key financial figures, technical analysis, and analyst ratings. The company, which specializes in developing and commercializing products for various therapies like Cushing's syndrome and severe hypoglycemia, currently holds a "Buy" rating from analysts with a target price of $11.286. Key metrics such as market cap, P/E ratio, and recent stock performance are detailed, alongside information on its product pipeline and major shareholders.
Mission Produce And Two Other Stocks Estimated To Be Trading Below Intrinsic Value
This article identifies Mission Produce, Xeris Biopharma Holdings, and Gold Royalty as three U.S. stocks currently trading below their estimated intrinsic value based on future cash flows. It provides an overview of each company's operations, estimated discount to fair value, and growth prospects, including forecasted earnings growth and recent financial performance. The analysis aims to help investors find potential opportunities for appreciation in a rising market.
Xeris Biopharma (XERS) insider Steven Pieper plans Rule 144 sale of 20,000 shares
Xeris Biopharma insider Steven Pieper has filed to sell 20,000 common shares under Rule 144, with an aggregate market value of $167,800.00, to be handled by Morgan Stanley Smith Barney LLC. These shares originated from Restricted Stock Units granted in January 2025. This planned sale follows previous 10b5-1 plan sales by Pieper in July 2026, totaling 45,000 shares for over $380,000.
Renaissance Technologies LLC Cuts Stock Position in Xeris Biopharma Holdings, Inc. $XERS
Renaissance Technologies LLC reduced its stake in Xeris Biopharma Holdings, Inc. by 26.9% in the first quarter, selling 166,800 shares but still owning 452,860 shares valued at approximately $2.63 million. Institutional investors collectively hold 42.75% of XERS, and analysts maintain a "Moderate Buy" consensus with an average price target of $10.80. Despite exceeding revenue estimates, Xeris reported an EPS loss of $0.18, and company insiders sold 266,499 shares worth about $2.0 million over the past three months.
Xeris Biopharma Holdings Inc (XERS) Stock News Today
This article provides current stock information for Xeris Biopharma Holdings Inc (XERS) including its recent closing price, market capitalization, and P/E ratio. It highlights that the company's stock experienced a gain of 7.74% and indicates that more news and earnings updates are expected soon for XERS.
Should Xeris Biopharma Holdings (XERS) Be Revalued After Strong Q2 Revenue And Fresh Guidance?
Xeris Biopharma Holdings (XERS) is attracting investor attention following its Q2 earnings report, which included strong performance and a refined full-year 2026 revenue outlook. The stock is currently trading at $7.93, with a recent 7.74% one-day return, and analysts consider it undervalued with a fair value estimated at $11.14. This valuation hinges on anticipated revenue growth from new product launches and margin expansion, despite concerns about rising R&D and SG&A expenses.
Xeris Biopharma Holdings, Inc. 2026: Revenue $92.1M, EPS ($0.18) — 10-Q Summary
Xeris Biopharma Holdings, Inc. reported its 2026 quarterly results with revenue reaching $92.1 million, an increase of 28.7% year-over-year. Despite the revenue growth, the company recorded a net loss of ($31.1M) and a diluted EPS of ($0.18), driven by higher product sales and increased operating investments. The growth was primarily fueled by an 80.6% surge in Recorlev sales and progress in its R&D pipeline for XP-8121.
Xeris Biopharma Holdings, Inc. reports results for the quarter ended June 30 - Earnings Summary
Xeris Biopharma Holdings, Inc. has released its earnings summary for the quarter that concluded on June 30. The report is provided by Refinitiv and is available to TradingView users with unlimited access to news articles.
Earnings call transcript: Xeris Biopharma posts Q2 2026 revenue beat, EPS miss
Xeris Biopharma reported a Q2 2026 revenue beat of $92.1 million, surpassing Wall Street estimates, but missed EPS expectations with a loss of $0.18 per share. The company attributed the EPS miss primarily to a one-time non-cash GAAP charge related to convertible note remeasurement. Despite the earnings miss, Xeris raised its full-year 2026 revenue guidance to $385 million-$390 million, driven by strong commercial momentum, particularly from RECORLEV, and the expected initiation of Phase III testing for XP-8121 by year-end.
Compared to Estimates, Xeris Biopharma (XERS) Q2 Earnings: A Look at Key Metrics
Xeris Biopharma (XERS) reported Q2 2026 revenue of $92.1 million, a 28.7% year-over-year increase, surpassing the Zacks Consensus Estimate. However, the EPS of $0 missed the consensus estimate of $0.02. Key product revenues varied, with Recorlev showing significant growth while Gvoke and Keveyis experienced declines.
(XERS) Xeris Biopharma Expects Full Year 2026 Revenue Range $385M - $390M, vs. FactSet Est of $385.9M
Xeris Biopharma Holdings, Inc. announced its full-year 2026 revenue guidance, projecting a range of $385 million to $390 million. This forecast is in line with FactSet's estimated revenue of $385.9 million. The company also provided an update on its second-quarter earnings for 2026.
Xeris Biopharma (NASDAQ:XERS) Insider Kevin Mcculloch Sells 15,000 Shares of Stock
Kevin Mcculloch, an insider at Xeris Biopharma (NASDAQ:XERS), sold 15,000 shares of the company's stock for $120,300 on August 3rd, reducing his total holdings by 0.89%. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan. The company's stock has shown positive performance, trading up at $8.19 with a market capitalization of $1.41 billion, and analysts maintain a "Moderate Buy" rating with an average price target of $10.80.
Xeris Biopharma (XERS) Insider Beth Hecht Sells 16,666 Shares
Xeris Biopharma insider Beth Hecht sold 16,666 shares of XERS for $8.01 per share on August 3, 2026, totaling approximately $133,495. This
Xeris Biopharma President, COO Kevin McCulloch sells 15,000 shares for $120,240
Xeris Biopharma President and COO Kevin McCulloch sold 15,000 common shares for $120,240 on August 3, 2026, at a price of $8.02 per share. Following this transaction, his direct stake increased to 1,676,126 shares. The report also noted his spouse indirectly holds 25,000 shares.
Vanguard Capital Management (XERS) discloses 8.64M-share, 5% holding in Xeris
Vanguard Capital Management LLC and its affiliates have reported a 5% beneficial ownership stake in Xeris Biopharma Holdings Inc, amounting to 8,637,640 common shares. This disclosure, made via a Schedule 13G filing, indicates that Vanguard holds sole voting power over 1,297,411 shares and sole dispositive power over all 8,637,640 shares. The filing confirms that no single person other than Vanguard has an interest exceeding 5% in the reported securities, which are held across various Vanguard funds and managed accounts.
XERS|Xeris Biopharma Holdings Inc|Price:8.415|Chg%:+0.035
This article provides a detailed financial overview of Xeris Biopharma Holdings Inc (XERS), including its stock price, market cap, P/E ratio, and upcoming earnings date. It presents comprehensive financial statements like the income statement, balance sheet, and cash flow statement, broken down quarterly and annually. The data highlights key financial indicators such as EPS, revenue, net profit, net margin, gross margin, and debt-to-assets ratio, along with FAQs summarizing recent fiscal year performance details.
Xeris Biopharma (XERS) Expected to Release Quarterly Earnings on Thursday
Xeris Biopharma (XERS) is scheduled to release its Q2 2026 earnings before market open on Thursday, August 6th. Analysts project earnings of $0.02 per share and approximately $90.1 million in revenue. The company currently holds a "Moderate Buy" consensus rating with an average price target of $10.80, although insiders have been net sellers of the stock recently.
Xeris Biopharma Holdings Inc (XERS) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of Xeris Biopharma Holdings Inc (XERS), noting its current valuation score of 8.01 within the Pharmaceuticals industry. It highlights the company's P/E ratio of 104.89, which is significantly below its recent high but above its recent low. Key valuation metrics like P/B, P/S, and P/CF are reported as not yet disclosed.
Xeris Biopharma Holdings Inc (XERS) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Xeris Biopharma Holdings Inc (XERS), detailing its current price momentum, support and resistance levels, and various technical indicators. The stock's price momentum score is 3.43, and it is trading between a resistance level of $8.98 and a support level of $7.81. The analysis also includes a summary of buy, sell, and neutral signals from indicators like MACD, RSI, and moving averages, concluding with an overall neutral signal based on moving averages and other technical indicators.
Xeris Biopharma Holdings Inc (XERS) Earnings Forecast: Future EPS & Revenue Growth Estimates
Xeris Biopharma Holdings Inc (XERS) has an earnings forecast score of 8.57, ranking 26th in the Pharmaceuticals industry. Analysts have an average price target of $10.00 for XERS, with a consensus "Buy" rating based on 7 analysts. The expected revenue for the next quarter is $90.22 million.
Rice Hall James & Associates LLC Acquires Shares of 251,066 Xeris Biopharma Holdings, Inc. $XERS
Rice Hall James & Associates LLC recently acquired 251,066 shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) worth approximately $1.46 million, contributing to institutional and hedge fund ownership of 42.75% of the company. Analysts maintain a "Moderate Buy" rating with a consensus target price of $10.80, despite recent insider share sales totaling about $1.85 million. Xeris Biopharma reported solid first-quarter earnings, exceeding revenue estimates.
Xeris Biopharma Holdings Inc (XERS) Cash Flow
This article provides a detailed quarterly and annual cash flow statement for Xeris Biopharma Holdings Inc (XERS), covering operating, investing, and financing activities. It presents financial data from FY2017Q1 through FY2026Q1, allowing users to evaluate the company's financial soundness. The report also includes FAQs explaining key cash flow concepts and Xeris Biopharma's performance in these areas.
Xeris Biopharma Holdings Inc (XERS) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article from TradingKey provides an overview of Xeris Biopharma Holdings Inc (XERS) focusing on its dividend and stock split history. It indicates that the company has not distributed any dividends over the past five years. The page also presents current stock price information, market capitalization, and P/E ratio for XERS.
Xeris Biopharma Holdings, Inc. Revenue Breakdown – NASDAQ:XERS
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) generated a total revenue of $291.85 million USD last year. The primary segment contributing to this revenue was "Gvoke, Keveyis and Recorlev," which brought in $283.00 million USD. The vast majority of the company's revenue, $291.85 million USD, was sourced from the United States.
